Company Reaffirms Guidance Anticipating Record FY2009 Sales and
Earnings CHICAGO, Feb. 10 /PRNewswire-FirstCall/ -- The Female
Health Company (NYSE Alternext: FHC), which manufactures and
markets the FC and FC2 Female Condoms(R), today reported its
operating results for the first quarter of FY2009. While unit sales
increased during the three months ended December 31, 2008, the
Company's net revenues decreased 7% to approximately $5.3 million,
compared with approximately $5.7 million in the first quarter of
the previous fiscal year. The decline in revenues reflects a
continuing shift in product shipments towards the Company's FC2
Female Condom(R), which is priced lower and generates a higher
gross profit margin than FC1. In addition, unit sales have been
temporarily limited by a significant increase in orders for FC1,
our first generation product, by customers requiring final FDA
approval to order FC2. At times, the increased demand has exceeded
our capacity to produce FC1. We elected not to invest in expanding
FC1 production capacity in anticipation of securing FC2 FDA
approval, discontinuing FC1 and investment in expanding FC2
production capacity. Given final FDA approval, it is anticipated
that these customers will purchase FC2, eliminating this temporary
limitation. The Company's net income attributable to common
shareholders increased 98% to $1,608,816, or $0.06 per diluted
share, during the first quarter of FY2009, compared with net income
attributable to common shareholders of $813,968, or $0.03 per
share, in the corresponding period of the previous fiscal year. The
Company was positively impacted by the strengthening of the U.S.
dollar relative to the British pound sterling in the first quarter
of FY2009, resulting in a foreign currency gain of $1,194,107,
compared with a currency gain of $115,358 in the first quarter of
FY2008. Gross profit increased 3% to $2,441,194 in the most recent
quarter, compared with $2,366,116 in the first quarter of FY2008.
Gross profit as a percentage of revenue totaled 45.7% in the first
quarter of FY2009, versus 41.3% in first quarter of FY2008.
Operating income decreased to $438,935, from $729,645 in the three
months ended December 31, 2007, due in part to significant one-time
expenses related to the Company's preparation for, and
participation in, the FDA OB/GYN Device Advisory Committee hearing
on December 11, 2008. Other expense increases included
compensations costs and Sarbanes Oxley internal control review
consulting. As noted in previous news releases, the Company expects
significant quarter-to-quarter variations in its operating results,
due to the timing of large order receipts, production scheduling,
and shipping of products. "We are pleased with first quarter
results, which were consistent with management's expectations,"
noted O.B. Parrish, Chief Executive Officer of The Female Health
Company. "The increasing acceptance of our second-generation FC2
Female Condom(R) and its favorable impact on our profitability is
particularly encouraging. We ended the first quarter with a strong,
debt-free balance sheet, approximately $3.3 million of cash in the
bank, and a current ratio of 4.3-to-1.0." "The event of greatest
significance during our first quarter occurred in December, when
the FDA's OB/GYN Advisory Panel voted unanimously to recommend
approval of FC2, so long as the labeling specifies the type of
clinical study on which the approval was based. We are presently
working through labeling details with the FDA for final approval,
which will allow us to market FC2 in the United States and to
provide it to the U.S. Agency for International Development
(USAID), one of our largest customers." "We are reaffirming our
annual guidance for FY 2009 that unit sales should increase 20% to
25% and that operating earnings should rise 50% to 75% from last
year's record levels," concluded Parish. As previously announced,
the Female Health Company will host an investor conference call at
11:00 a.m. EST today, February 10, 2009. Shareholders and other
interested parties may participate in the conference call by
dialing 800-860-2442 (international participants dial 412-858-4600)
and asking to be connected to "The Female Health Company Conference
Call", a few minutes before 11:00 a.m. EST on February 10, 2009. A
replay of the call will be available one hour after the call
through 5:00 p.m. EST on February 24, 2009 by dialing 877-344-7529
(international callers dial 412-317-0088) and entering the
conference ID 427502. About The Female Health Company The Female
Health Company, based in Chicago, Illinois, manufactures and
markets the FC Female Condom(R), (FC1) and the FC2 Female Condom
(FC2), which are primarily distributed by public health
organizations and donor groups in over 90 developing countries
around the world. Globally, the Female Condoms are available in
various programs in 116 countries. The Company owns certain
worldwide rights to the FC Female Condom(R), including patents that
have been issued in the United States, United Kingdom, Japan,
France, Italy, Germany, Spain, the European Patent Convention, the
People's Republic of China, Canada, South Korea and Australia. FC
Female Condom(R) is the only available FDA- approved product
controlled by a woman that offers dual protection against sexually
transmitted diseases, including HIV/AIDS, and unintended pregnancy.
For more information about the Female Health Company visit the
Company's web site at http://www.femalehealth.com/ and
http://www.femalecondom.org/. If you would like to be added to an
e-mail alert list, please send an e-mail to "Safe Harbor" statement
under the Private Securities Litigation Reform Act of 1995: The
statements in this release which are not historical fact are
"forward- looking statements" as that term in defined in the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements in this release include the Company's financial guidance
for fiscal 2009. These statements are based upon the Company's
current plans and strategies, and reflect the Company's current
assessment of the risks and uncertainties related to its business,
and are made as of the date of this release. The Company assumes no
obligation to update any forward-looking statements contained in
this release as a result of new information or future events,
developments or circumstances. Such forward-looking statements are
inherently subject to known and unknown risks and uncertainties.
The Company's actual results and future developments could differ
materially from the results or developments express in, or implied
by, these forward-looking statements. Factors that may cause actual
results to differ materially from those contemplated by such
forward-looking statements include, but are not limited to, the
following: product demand and market acceptance; competition in the
Company's markets and the risk of new competitors and new
competitive product introductions; The Company's reliance on its
international partners in the consumer sector and on the level of
spending on the female condom by country governments; global donors
and other public health organizations in the global public sector;
the economic and business environment and the impact of government
pressures, risks involved in doing business on an international
level, including currency risks, regulator requirements, political
risks, export restrictions and other trade barriers; the Company's
production capacity, efficiency and supply constraints; and other
risks detailed in the Company's press releases, shareholder
communication and Securities and Exchange Commission filings,
including the Company's form 10-K for the fiscal year ended
September 30, 2008. Actual events affecting the Company and the
impact of such events on the Company's operations may vary from
those currently anticipated. The Female Health Company Unaudited
Condensed Consolidated Balance Sheets December 31, December 31,
2008 2007 Cash $3,190,841 $1,604,306 Restricted cash 173,970
236,138 Accounts receivable, net 3,444,439 6,007,114 Inventory
1,817,324 1,785,430 Prepaid and other current assets 282,884
328,516 Deferred income taxes 1,600,000 825,000 Total current
assets 10,509,458 10,786,504 Other non-current assets 56,000
246,853 Net property, plant & equipment 1,446,858 1,477,667
Total assets $12,012,316 $12,511,024 Accounts payable $1,047,221
$1,129,725 Accrued expenses 1,374,249 1,818,791 Preferred dividends
payable 24,575 48,643 Total current liabilities 2,446,045 2,997,159
Obligations under capital leases 30,573 58,888 Deferred gain on
sale of facilities 666,233 1,017,317 Deferred grant income 161,382
247,567 Total liabilities 3,304,233 4,320,931 Total stockholders'
equity 8,708,083 8,190,093 Total liabilities and stockholders'
equity $12,012,316 $12,511,024 The Female Health Company Unaudited
Condensed Consolidated Income Statements Three Months Ended
December 31, 2008 2007 Net revenues $5,344,838 $5,734,751 Cost of
products sold 2,903,644 3,368,635 Gross profit 2,441,194 2,366,116
Advertising and promotion 70,794 41,518 Selling, general and
administrative 1,861,045 1,493,824 Research and development 70,420
101,129 Total operating expenses 2,002,259 1,636,471 Operating
income 438,935 729,645 Interest, net and other income (8,889)
(9,608) Foreign currency transaction gain (1,194,107) (115,358)
Income before income taxes 1,641,931 854,611 Income tax expense
8,540 - Net income 1,633,391 854,611 Preferred dividends 24,575
40,643 Net income attributable to common stockholders $1,608,816
$813,968 Net income per basic common share outstanding $0.06 $0.03
Basic weighted average common shares outstanding 25,820,224
26,121,460 Net income per diluted common share outstanding $0.06
$0.03 Diluted weighted average common shares outstanding 27,984,633
28,688,345 DATASOURCE: The Female Health Company CONTACT: William
R. Gargiulo, Jr., +1-231-526-1244, or Donna Felch, CFO,
+1-312-595-9123, both of The Female Health Company Web site:
http://www.femalehealth.com/ http://www.femalecondom.org/
Copyright